DB08904 in Crohn 's disease . DB08904 is a humanized Fab ' fragment monoclonal antibody to tumor necrosis factor alpha ( P01375 ) . PEGylation increases its half-life , and it is administered subcutaneously to treat immune-mediated inflammatory diseases such as Crohn 's disease and rheumatoid arthritis . DB08904 improves quality of life and reduces clinical disease activity . Inflammatory markers such as P02741 ( CRP ) also decrease after administration of certolizumab pegol . The dose for induction of remission is 400 mg subcutaneously at weeks 0 , 2 and 4 . The dose for maintenance of remission is 400 mg sc given every four weeks . The safety profile is comparable with other anti- P01375 agents , and the major adverse events are related to infections . This article reviews the published data regarding the efficacy and safety of certolizumab pegol .